Advarra was recapitalized with investment from Genstar Capital.

Genstar Capital, a leading private equity firm with expertise in drug research and healthcare, completed its acquisition of Advarra, the premier provider of institutional review board, institutional biosafety committee, and compliance and regulatory consulting services, from Linden Capital Partners. Financial terms were not disclosed. “Advarra’s leadership has built a company with a stellar reputation in the pharmaceutical regulatory compliance industry that provides unmatched service, user-friendly technology, and rapid turn-around times. We are excited to support Advarra in continuing to build upon its leading reputation, while expanding, both organically and through strategic acquisitions, into other ancillary services to continue adding value for its customers,” David Golde, Genstar Capital Managing Director.